© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Liranaftate stands out as a topical antifungal agent found in creams and other pharmaceutical forms used to treat skin infections like athlete’s foot and ringworm. This compound belongs to the class of thiocarbamate antifungals. The chemical structure reveals a combination of a naphthalene ring fused to a thiocarbamate group, which targets fungal cell walls and disrupts their development. Liranaftate carries the molecular formula C18H17NOS, and the molar mass lands at 295.4 g/mol. Those numbers might not mean much for everyday conversation, but to pharmaceutical chemists and safety teams, every detail matters. HS Code for this product often cuts through customs and regulatory systems under 2930.90, classified as an organic chemical containing a heteroatom.
Pure Liranaftate appears as a white or nearly white solid, typically found in polymorphic forms like flakes, crystalline powder, or small pearls. Density has shown to hover around 1.25 g/cm³, which helps when measuring out precise doses for laboratory and industrial purposes. It melts at approximately 107–110°C, providing useful information for those concerned about storage conditions or application processes in warmer climates. In practical handling, Liranaftate offers a faint odor, neither pleasant nor strong, and resists dissolving in water. Solubility rises substantially in organic solvents like ethanol, acetone, and chloroform, a factor that influences the base of many topical formulations. Material stability at typical ambient conditions helps reduce risk during transport but users keep a close eye on temperature and humidity to avoid unwanted clumping or degradation.
Typical supplied forms include both pharmaceutical-grade powder and intermediate forms for use in research or downstream processing. Details like minimum assay percentage and impurity thresholds get checked batch by batch, with analytical results guiding whether a shipment gets green-lit for further use. Liranaftate is not classified as explosively hazardous, though handling guidelines from chemical safety authorities require gloves and eye protection. Direct inhalation or contact with eyes should be avoided, since mild irritation can result, especially in sensitive individuals. Safety data points out that the product should be kept tightly sealed in its original container, away from direct sunlight or sources of ignition, both to maintain the material’s integrity and to reduce any risk to handlers. Shipping documentation must reference the molecular details, batch records, and at times the HS Code to meet customs and regulatory demands.
Experience in both laboratory and manufacturing settings suggests that most risks center around inappropriate handling. Liranaftate qualifies as a chemical raw material, which means that once improperly stored or used, the risk of contamination and misuse rises. Inhalation and long-term skin exposure, while not common routes of significant toxicity, should still be minimized, according to occupational health recommendations. Scientific reports link repeated, high-dose exposure in animals to minor disruptions in liver enzyme levels, but at the low doses associated with routine topical application in humans, incidence of adverse effects stays limited. Disposal procedures for expired or off-specification lots insist on environmentally safe practices, noting that release into surface water or soil should be prevented to avoid impact on local ecosystems.
Pharmaceutical manufacturers and formulation chemists handle Liranaftate as a defined raw material, not a ready-to-use medicine. Its journey from raw powder to finished solution demands strict cleanroom practices, thorough lot testing, and a clear chain of custody from shipment receipt to final blending. Chemical suppliers emphasize traceability for every drum or container, as regulations — particularly across borders in Europe and North America — demand full documentation. Reliable supply chains remain critical: production of finished antifungal drugs depends on consistency in crystalline morphology and purity of the starting material. Material shortages or lapses in quality control could introduce delays in medication supply, or, in the worst case, withdrawal for safety reasons. Cross-checking certifications, such as certificates of analysis and MSDS sheets, keeps both the handlers and downstream users informed and safe.
Anyone who has dealt with persistent athlete’s foot or similar infections can attest to the value of efficient, well-formulated antifungal creams. Liranaftate’s chemical sophistication enables disruption of pathogenic fungi while sparing healthy skin. Decades of research into thiocarbamate compounds, coupled with detailed toxicology studies, have yielded a product that not only meets international safety benchmarks but also continues to feature in routine medical kits across hospitals, clinics, and pharmacies. Continued education of pharmacological staff, custom agents, and public health officers ensures that every gram of raw Liranaftate passes through the proper checks, maintaining both efficacy and user safety from production facility through to consumer use.
Protecting the users and handlers of Liranaftate starts with a well-designed set of protocols. Training sessions for on-site workers, detailed labeling systems, and regular audits ensure compliance. Investing in high-quality storage solutions, such as humidity-controlled cabinets, further protects product quality over extended periods. Every case of accidental exposure should be met with direct action: immediate rinsing with water, medical consultation, and full reporting. Waste management teams establish secure collection and disposal processes for expired or contaminated stocks, reducing the risk of harmful environmental impact. Encouraging open communication between manufacturers, suppliers, logistics personnel, and medical end-users positions Liranaftate as a trusted, safe, and effective solution — upholding both public health and environmental stewardship in all phases of its lifecycle.
